Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
Date:7/9/2008

s uveitis.

About Noninfectious Uveitis

Uveitis is an inflammation of the internal structures of the eye. Uveitis can be described by the underlying condition that causes it: autoimmune (noninfectious), bacterial, viral, parasitic and eye trauma, and by the part of the eye that it affects: anterior, intermediate, posterior and panuveitis. Noninfectious uveitis affects approximately two hundred forty thousand people worldwide and can lead to complications, such as glaucoma, cataract and total vision loss. Current treatments include topical and oral corticosteroids, steroidal implants and immunosuppressive drugs; however, these generally have limited success and can lead to adverse events.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians to further improve the lives of their patients.

Cerimon currently has two drugs in clinical development. The Company's autoimmune program has two development programs. The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for noninfectious uveitis in a Phase II study. Cerimon's lead asset in its pain portfolio is the Company's topical formulations of diclofenac. The Company is in mid-stage clinical testing with its topical diclofenac products.

The Company continues to seek additional assets to add to its development pipeline and is financed by the premier investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com .


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... pleased to announce their partnership with Apex Physical Therapy (Apex) is ... continue to provide kind, compassionate, and empathetic care to local residents from their ...
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
(Date:9/1/2015)... ... 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... the LATINA Style 50 Report that recognizes companies that provide the best career opportunities ... BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for Latinas. ...
(Date:9/1/2015)... Rolling Meadows, Ill. (PRWEB) , ... September 01, ... ... medical procedures done by members of the American Society for Dermatologic Surgery, according ... case. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which ...
(Date:9/1/2015)... London, UK (PRWEB) , ... September 01, 2015 ... ... of a vacuum that creates negative pressure inside a wound to remove exudates, ... market for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, ...
Breaking Medicine News(10 mins):Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... study did find possible protection against colon tumors, however , , ... vitamin D did not lower the overall cancer death rate ... note a marked reduction in colorectal cancer deaths linked to ... U.S. National Cancer Institute, run counter to some earlier data ...
... 30 Roper Industries,Inc. (NYSE: ROP ) announced ... Conference on Tuesday, November 6, 2007 at 1:20 PM ... copy of the presentation,will be available in the "Investor ... About Roper Industries Roper Industries is a ...
... N.Y., Oct. 30 The North-Shore LIJ,Health System ... from the founders of Melville, NY-based FalconStor Software ... The gift will be used to create ... throughout the greater Flushing, NY area. Site,selection is ...
... Centers for Disease Control, University of Cologne and Selera ... Pathology (AMP) Annual Conference , When: Wednesday, Nov. 7, 9:00 ... Los Angeles , Why: Since the first diagnostic tests for ... public health authorities have been concerned about HIVs ability ...
... S.A. (Nasdaq:,EDAP) the global leader in High Intensity ... has entered into a securities purchase,agreement with selected ... which the Investors will purchase US $20 million,in ... will be delivered in the form of American ...
... IDEV ) today announced the Company will be,presenting ... on,Tuesday, November 6, 2007 at 2:30 PM Eastern Time. ... Rodman & Renshaw 9th Annual Healthcare,Conference on Wednesday, November ... being held in New York City. The presentations will ...
Cached Medicine News:Health News:Vitamin D Won't Help Prevent Most Cancers 2Health News:Vitamin D Won't Help Prevent Most Cancers 3Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 2Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 3Health News:Indevus Pharmaceuticals to Present at Upcoming Investor Conferences 2Health News:Indevus Pharmaceuticals to Present at Upcoming Investor Conferences 3
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
... (cTnI) has been useful in the differential ... (ED) with chest pain. 18-20 ... levels of sensitive and specific biomarkers, such ... creatine kinase (CK-MB), and myoglobin, are increased ...
Medicine Products: